Anticonvulsant activity of N-methylcytisine hydrobromide

Abstract

This study presents a comprehensive evaluation of the acute toxicity profile and anticonvulsant potential of N-methylcytisine hydrobromide using validated experimental animal models. Although N-methylcytisine hydrobromide is structurally derived from cytisine, it exhibits distinct pharmacological characteristics that differentiate it from its parent compound. Notably, N-methylcytisine functions as a competitive antagonist of nicotinic acetylcholine receptors, thereby modulating neuronal excitation processes within the central nervous system. This mechanism is considered a key contributor to its observed anticonvulsant effects. In the thiosemicarbazide-induced seizure model, administration of N-methylcytisine hydrobromide contributed to the restoration of the balance between excitatory and inhibitory neurotransmission at the level of interneuronal signaling. This regulatory effect resulted in a marked reduction in central nervous system hyperexcitability, as evidenced by a decrease in both the severity and duration of seizure activity. These findings suggest that the compound exerts a stabilizing influence on neurochemical processes associated with seizure generation. Furthermore, pronounced anticonvulsant activity was observed across multiple experimental seizure paradigms, including strychnine- and corazole-induced convulsion models. Importantly, the efficacy of N-methylcytisine hydrobromide in these models was comparable to that of established antiepileptic drugs, such as carbamazepine and convulex, which are widely used in clinical practice. Collectively, these results highlight the significant anticonvulsant potential of N-methylcytisine hydrobromide and support its consideration as a promising candidate for further develo p ment as an antiepileptic agent. Additional pharmacological and clinical investigations are warranted to fully elucidate its therapeutic profile and mechanisms of action.